Antimicrobial resistance remains one of the most formidable challenges confronting global health systems, undermining decades of medical progress. The researchers recognized that an essential step in curbing this threat involves focusing resources and surveillance efforts on pathogens that contribute most significantly to resistant infections. Canada’s AMR prioritization framework leverages robust datasets encompassing clinical isolates, resistance phenotypes, infection prevalence, and associated morbidity and mortality metrics to construct a scientifically grounded hierarchy. This stratification is especially pivotal in informing drug development pipelines, infection control policies, and stewardship programs to optimize resource allocation amid constrained healthcare budgets.

The framework’s dual consideration of pathogens prevalent in both hospital and community settings marks a critical evolution in AMR strategy. Traditionally, surveillance systems have skewed toward nosocomial infections, but this research underscores the growing public health impact of resistant bacteria transmitted in community settings. Notably, sexually transmitted infections (STIs), such as resistant strains of Neisseria gonorrhoeae, have been incorporated due to their rising incidence and dwindling therapeutic options, reflecting an urgent call for expanded monitoring and tailored public health responses beyond hospital walls.

In constructing their prioritization algorithm, the authors employed multi-criteria decision analysis techniques, integrating pathogen-specific data on transmission dynamics, resistance mechanisms, treatability, and the availability of alternative therapies. This complex analytical model balances quantitative data with expert consensus, thereby refining traditional approaches and accommodating emerging resistance patterns. Such rigorous methodological underpinning ensures that the prioritization is both transparent and adaptable, capable of guiding dynamic surveillance and intervention strategies in the face of evolving bacterial threats.

The publication further elucidates the public health ramifications of the identified priority pathogens, illustrating how their resistance profiles exacerbate clinical outcomes, escalate treatment costs, and complicate infection control measures. For instance, the pervasive presence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae highlights the urgent need for novel antimicrobial agents and enhanced diagnostic capabilities. Meanwhile, drug-resistant Mycobacterium tuberculosis remains a global concern due to its protracted treatment regimens and significant transmission potential, emphasizing the framework’s comprehensive reach beyond conventional pathogens.

One of the study’s salient contributions lies in its policy-oriented focus, offering actionable insights for healthcare authorities. By pinpointing priority pathogens with precision, the framework enables the tailoring of antimicrobial stewardship efforts, guided surveillance programs, and investment in research and development. This alignment between scientific evidence and practical application stands to accelerate the impact of public health interventions, ultimately mitigating the progression of resistance and preserving the efficacy of existing antibiotics for future generations.

The inclusion of sexually transmitted pathogens within the prioritization reflects an enlightened shift toward recognizing the complex interface between infectious disease epidemiology and social behavior. Resistant STIs pose significant challenges due to their stealthy transmission, stigmatization, and often asymptomatic nature, which allow silent propagation within populations. The study advocates for expanded diagnostic screening, enhanced public awareness, and the integration of STI resistance data into national AMR monitoring systems, thereby addressing a critical gap in conventional surveillance models.

Moreover, the Canadian framework serves as a potential blueprint for other nations grappling with similar AMR threats, demonstrating how localized data can be harnessed to generate context-specific strategies. The methodology’s adaptability allows for incorporation of regional variations in pathogen prevalence, healthcare infrastructure, and antibiotic usage patterns, making it a versatile tool in the global fight against resistance. Such harmonization of data-driven prioritization may foster collaborative efforts, optimize global resource distribution, and align international policy frameworks.

The study also highlights the pivotal role of interdisciplinary collaboration, bringing together microbiologists, epidemiologists, clinicians, and public health officials to construct an integrative assessment of AMR risks. This cooperative model ensures that the prioritization encompasses diverse expertise and reflects real-world complexities, strengthening the validity and applicability of the findings. It underscores the necessity for continued partnerships across sectors to sustain momentum in AMR mitigation efforts.

Importantly, the authors acknowledge limitations inherent in current data systems, including underreporting and diagnostic inconsistencies, which may influence pathogen ranking. They call for enhanced surveillance infrastructure, improved laboratory capacity, and standardized resistance reporting to refine future iterations of the prioritization framework. Such enhancements will not only bolster the accuracy of pathogen rankings but also provide critical feedback loops to health systems adapting to changing AMR landscapes.

The broader implications of this evidence-based framework extend to global health security, where the containment of resistant pathogens is paramount. By offering a replicable, data-driven approach to pathogen prioritization, the Canadian study contributes significantly to international discourse on AMR management, emphasizing prevention, early detection, and responsive policy development. Its insights resonate beyond national borders, advocating for a coordinated response to what WHO classifies as one of the top ten global public health threats.

As the medical community anticipates the continued evolution of antimicrobial resistance, such innovative frameworks provide a beacon of evidence-driven hope. Through strategic prioritization and targeted public health action, it becomes feasible to curtail the spread of resistant infections, safeguard therapeutic efficacy, and protect vulnerable populations. This study ultimately exemplifies the vital intersection of science, policy, and health practice in addressing one of the most pressing contemporary biomedical challenges.

Subject of Research:
Antimicrobial resistance prioritization of bacterial pathogens in Canada for 2025, focusing on healthcare and community-associated infections including sexually transmitted infections.

Article Title:
Canada’s 2025 AMR priority pathogens: Evidence-based ranking and public health implications

News Publication Date:
17-Sep-2025

Web References:
http://dx.doi.org/10.1371/journal.pone.0330128

Image Credits:
Aanchal Mishra, CC-BY 4.0

Keywords:
Antimicrobial resistance, bacterial pathogens, prioritization framework, public health, sexually transmitted infections, healthcare-associated infections, surveillance, drug resistance, Canada, evidence-based ranking

Center for Emerging and Infectious Diseases

The Center for Emerging and Infectious Diseases (CEID) will contribute to the ongoing advancement of diagnostic testing, enabling rapid and accurate identification of infectious agents. The center’s researchers will engage with local and global communities to better understand disease transmission patterns, devise evidence-based strategies for prevention and control, and enhance public health preparedness. The epidemiological work that will take place within CEID will allow public health agencies to make informed decisions, particularly in times of urgent need, and allocate resources effectively.

“The mission of the Center for Emerging and Infectious Diseases is to develop, evaluate and implement effective countermeasures against existing and emerging infectious disease threats,” said Marcus Zervos, M.D., co-director of the center. “Along with co-directors Teena Chopra, M.D., MPH, and Paul Kilgore, M.D., CEID will conduct basic, clinical and applied research to accelerate development and introduction of vaccines and related interventions to control emerging and re-emerging infectious diseases affecting populations in Detroit, Michigan, the United States and around the world. This center will be a unique resource within the Wayne State University and Detroit communities and beyond that will enable rapid implementation of research teams to prepare clinical vaccine trials in outpatient, inpatient and community settings.”

CEID’s programs will provide credible, evidence-based information to guide informed decision-making for participation in clinical trials as well as utilization of proven tools that enhance preparedness and protect communities from diseases of epidemic and pandemic potential.

“It is our goal to be an important resource for many to understand emerging and infectious diseases that have increased mortality and morbidity impact,” said Zervos. “In particular, communities such as Detroit often have less direct access to information, and the center will play a critical role in providing our citizens with critical communications that can ultimately impact the health of themselves as well as their friends and family.”

“CEID’s state-of-the-art microbiology laboratory has capabilities for rapid detection of emerging and re-emerging infectious diseases,” said Chopra. “This will provide quality and timely care to Detroit residents.”

Hossein Salimnia, Ph.D., serves as the microbiology director of the lab and Chopra is the medical director.

Ben L. Silberstein Institute for Brain Health

The Ben L. Silberstein Institute for Brain Health (IBH) will advance the understanding of the brain’s structure, chemistry and function as it relates to both disease and the promotion of health and well-being. It will accelerate and promote team interactional science through biomedical imaging platforms, neurogenetics, addiction and pain biology, post-traumatic stress disorder and trauma neurobiology, gerontology nanotechnology, neurodevelopment, targeting and reducing health care disparities, and innovative and novel diagnostic and treatment development.

“The Ben L. Silberstein Institute for Brain Health will bring together transdisciplinary, cross-campus neuroscience researchers, as well as combine undergraduate, graduate and post-doctoral neuroscience education to focus on health equity and challenges related to brain and behavioral health in urban environments, particularly in Southeast Michigan and Detroit,” said David Rosenberg, co-director of IBH. “It is our goal to make a significant impact on promoting brain health by targeting and accelerating diagnostic and therapeutic advances for real-world childhood and adult-onset brain disorders impacting our community and beyond.”

IBH aims to be a leader in translational neurosciences and inspire the next generation of students and researchers to improve the health and care of individuals affected by psychiatric or neurological disorders or injuries in the nervous system. The institute will identify mechanisms promoting brain health as well as enhancing the understanding of disease mechanisms as it can related to enhanced diagnosis and treatment, ultimately aiding many with real-world childhood and adult-onset brain disorders.

“IBH will work with strategic partners and faculty across campus to improve lives through important research and community outreach that will provide diagnosis and new treatments for many psychiatric and brain disorders,” said Rosenberg. “By building a large collaborative team, we are now better able to facilitate the important work that needs to be done to help the lives of so many impacted by brain health issues.”

“Wayne State University is committed to improving the lives of our community and beyond, and through the Center for Emerging and Infectious Diseases and the Ben L. Silberstein Institute for Brain Health, we are now well positioned to be a leader in Detroit for advancing research, technology development and education in these critical health areas,” said Stemmler. “Collaboration is a critical component of research, and these two institutes will be excellent examples of how bringing disciplines from across campus together can lead to groundbreaking discoveries that will improve lives.”

###

About Wayne State University

Wayne State University is one of the nation’s pre-eminent public research universities in an urban setting. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, state of Michigan and throughout the world. For more information about research at Wayne State University, visit research.wayne.edu.

Contact info
Julie O’Connor
Director, Research Communications
Phone: 313-577-8845
Email: julie.oconnor@wayne.edu